31 – 40 of 48
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2002
-
Mark
FDG PET studies during treatment: Prediction of therapy outcome in head and neck squamous cell carcinoma.
(
- Contribution to journal › Article
-
Mark
Time dependence of the activity concentration ratio of red marrow to blood and implications for red marrow dosimetry.
(
- Contribution to journal › Article
-
Mark
131I-labelled anti-CD22 MAb (LL2) in patients with B-cell lymphomas failing chemotherapy. Treatment outcome, haematological toxicity and bone marrow absorbed dose estimates.
(
- Contribution to journal › Article
- 2001
-
Mark
Durable response to 90-yttrium-Epratuzumab (hLL2) in B-cell lymphoma failing chemotherapy by using dose-fractionation schedule
(
- Contribution to journal › Article
- 2000
-
Mark
Extracorporeal techniques in radioimmunotherapy
2000) p.223-243(
- Chapter in Book/Report/Conference proceeding › Book chapter
- 1999
-
Mark
Radioimmunotherapy using 131I-labeled anti-CD22 monoclonal antibody (LL2) in patients with previously treated B-cell lymphomas
(
- Contribution to journal › Article
- 1997
-
Mark
Extracorporeal whole-blood immunoadsorption enhances radioimmunotargeting of iodine-125-labeled BR96-biotin monoclonal antibody
(
- Contribution to journal › Article
-
Mark
Early prediction of treatment outcome in head and neck cancer with 2-18FDG PET
(
- Contribution to journal › Article
- 1996
-
Mark
Extracorporeal immunoadsorption from whole blood based on the avidin-biotin concept. Evaluation of a new method
(
- Contribution to journal › Article
-
Mark
Biodistribution and pharmacokinetics of 125I/131I pair-labelled biotinylated chimeric BR96 in colon carcinoma isografted rats
(
- Contribution to journal › Article